Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Vanja Vaccaro"'
Autor:
Guido Giordano, Michele Milella, Matteo Landriscina, Francesca Bergamo, Giuseppe Tirino, Antonio Santaniello, Alberto Zaniboni, Enrico Vasile, Ferdinando De Vita, Giovanni Lo Re, Vanja Vaccaro, Elisa Giommoni, Donato Natale, Raffaele Conca, Daniele Santini, Luigi Maiorino, Gianni Sanna, Vincenzo Ricci, Aldo Iop, Vincenzo Montesarchio, Letizia Procaccio, Silvia Noventa, Roberto Bianco, Antonio Febbraro, Sara Lonardi, Giampaolo Tortora, Isabella Sperduti, Davide Melisi
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Pancreatic cancer (PC) first‐line therapy often consists of polychemotherapy regimens, but choosing a second‐line therapy after disease progression, especially following first‐line FOLFIRINOX, remains a clinical challenge. T
Externí odkaz:
https://doaj.org/article/cf916ab2ef1c4b38b23365ff3e0dccbd
Autor:
Letizia Procaccio, Valeria Merz, Morena Fasano, Vanja Vaccaro, Elisa Giommoni, Andrea Pretta, Silvia Noventa, Maria Antonietta Satolli, Guido Giordano, Clizia Zichi, Carmine Pinto, Camilla Zecchetto, Giulia Barsotti, Ferdinando De Vita, Michele Milella, Lorenzo Antonuzzo, Mario Scartozzi, Alberto Zaniboni, Rosella Spadi, Simona Casalino, Francesca Bergamo, Chiara De Toni, Davide Melisi, Sara Lonardi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14337-14345 (2023)
Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) prog
Externí odkaz:
https://doaj.org/article/2ba909e629d843ce87c0d79ae0e1a3c6
Autor:
Elisa Giommoni, Evaristo Maiello, Vanja Vaccaro, Ermanno Rondini, Caterina Vivaldi, Giampaolo Tortora, Laura Toppo, Guido Giordano, Tiziana Pia Latiano, Cinzia Lamperini, Serena Pillozzi, Luca Boni, Lorenzo Antonuzzo, Francesco Di Costanzo
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 1761-1772 (2021)
Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most pat
Externí odkaz:
https://doaj.org/article/af7cf3f9c61f4f568a09f101f8505b66
Autor:
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casadei, Alessio Cortellini, Francesco Verderame, Vincenzo Montesarchio, Mimma Rizzo, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Saverio Cinieri, Giorgia Negrini, Maria Banzi, Mariella Sorarù, Paolo Andrea Zucali, Gaetano Lacidogna, Antonio Russo, Nicola Battelli, Giuseppe Fornarini, Claudia Mucciarini, Sergio Bracarda, Andrea Bonetti, Debora Pezzuolo, Lucia Longo, Donata Sartori, Mauro Iannopollo, Luigi Cavanna, Fausto Meriggi, Davide Tassinari, Claudia Corbo, Angela Gernone, Veronica Prati, Simona Carnio, Pasqualina Giordano, Angela Maria Dicorato, Claudio Verusio, Francesco Atzori, Francesco Carrozza, Stefania Gori, Antonino Castro, Sara Pilotto, Vanja Vaccaro, Elisabetta Garzoli, Francesco Di Costanzo, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Michele Tognetto, Sebastiano Buti
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from O
Externí odkaz:
https://doaj.org/article/56f65524e4484c51b38e78016965cac1
Autor:
Chiara Bazzichetto, Claudio Luchini, Fabiana Conciatori, Vanja Vaccaro, Ilaria Di Cello, Paola Mattiolo, Italia Falcone, Gianluigi Ferretti, Aldo Scarpa, Francesco Cognetti, Michele Milella
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 22, p 8841 (2020)
To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to the lack of early diagnosis and personalized treatment strategies. In this context, the possibility and the opportunity of identifying genetic and molecula
Externí odkaz:
https://doaj.org/article/9fbe8f8559894d1896ce92e9651eca8e
Autor:
Chiara Bazzichetto, Fabiana Conciatori, Claudio Luchini, Francesca Simionato, Raffaela Santoro, Vanja Vaccaro, Vincenzo Corbo, Italia Falcone, Gianluigi Ferretti, Francesco Cognetti, Davide Melisi, Aldo Scarpa, Ludovica Ciuffreda, Michele Milella
Publikováno v:
Cells, Vol 9, Iss 2, p 309 (2020)
The threatening notoriety of pancreatic cancer mainly arises from its negligible early diagnosis, highly aggressive progression, failure of conventional therapeutic options and consequent very poor prognosis. The most important driver genes of pancre
Externí odkaz:
https://doaj.org/article/06891359fa144ed89c24fb7e14fc01d5
Autor:
Luisa Carbognin, Sara Pilotto, Michele Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi, Vincenzo Bronte, Aldo Scarpa, Emilio Bria, Giampaolo Tortora
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0130142 (2015)
The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD-1 pathway represents an issue for clinical research.Overall response rate (
Externí odkaz:
https://doaj.org/article/ee78a6d6da5f4636b0914b280cfd4efd
Autor:
Piero Ferolla, Alfredo Berruti, Francesca Spada, Maria Pia Brizzi, Toni Ibrahim, Riccardo Marconcini, Dario Giuffrida, Vito Amoroso, Anna La Salvia, Vanja Vaccaro, Antongiulio Faggiano, Annamaria Colao, Marco Volante, Simona Ghizzoni, Paola Mazzanti, Aude Houchard, Nicola Fazio
Publikováno v:
Neuroendocrinology. 113:332-342
Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410)
Autor:
M. Reni, E. Giommoni, F. Bergamo, M. Milella, L. Cavanna, M.C. Di Marco, M. Spada, S. Cordio, G. Aprile, G.G. Cardellino, E. Maiello, I. Bernardini, M. Ghidini, S. Bozzarelli, M. Macchini, G. Orsi, I. De Simone, Er. Rulli, L. Porcu, V. Torri, C. Pinto, Michele Reni, Marina Macchini, Giulia Orsi, Umberto Peretti, Mariamaddalena Valente, Elisa Giommoni, Lorenzo Antonuzzo, Francesco Di Costanzo, Francesca Bergamo, Vittorina Zagonel, Sara Lonardi, Federica Buggin, Michele Milella, Silvia Palmerio, Luigi Cavanna, Camilla Di Nunzio, Maria Cristina Di Marco, Elisa Grassi, Massimiliano Spada, Marco Messina, Stefano Cordio, Francesco Avola, Giuseppe Aprile, Salvatore Pagano, Francesca Simionato, Giovanni Gerardo Cardellino, Federica Majer, Evaristo Maiello, Tiziana Pia Latiano, Cinzia Chiarazzo, Fabrizio Artioli, Giorgia Razzini, Antonella Pasqualini, Michele Ghidini, Elisa Binda, Silvia Lazzarelli, Silvia Bozzarelli, Simona Sala, Gabriele Luppi, Elisa Pettorelli, Andrea Spallanzani, Giovanni Vicario, Flavia Salmaso, Marco Basso, Nicola Silvestris, Sabina Del Curatolo, Fable Zustovich, Francesca Bongiovanni, Ciro Longobardi, Ilenia Sandi, Caterina Fontanella, Silvia Montelatici, Monica Giordano, Giovanna Luchena, Micol Gilardoni, Emiliano Tamburini, Britt Rudnas, Barbara Venturini, Barbara Merelli, Giorgia Negrini, Elio Maria Vici, Alessandra Marabese, Cristina Garetto, Paola Curcio, Saverio Cinieri, Margherita Cinefra, Pasqualinda Ferrara, Maurizio Cantore, Patrizia Morselli, Guglielmo Fumi, Agnese Isidori, Giovanni Ciccarese, Giovanni Luca Paolo Frassineti, Flavia Pagan, Vanja Vaccaro, Chiara Spoto, Marianna Ferrara, Carlo Garufi, Marta Caporale, Enrico Vasile, Francesca Salani, Elisa Barone, Rossana Berardi, Azzurra Onofri, Zelmira Ballatore, Alessandra Lucarelli, Alessandra Barucca, Amedeo Pancotti, Teresa Scipioni, Katia Bencardino, Giovanna Marrapese, Laura Idotta, Fausto Petrelli, Veronica Lonati, Anna Ceribelli, Angelo Giuli, Cristina Zannori, Maria Bassanelli, Andrea Mambrini, Laura Ginocchi, Massimo Orlandi, Luigi Celio, Monica Niger, Lavinia Biamonte, Stefano Tamberi, Alessandra Piancastelli, Giorgio Papiani, Irene Valli, Paolo Allione, Maria Giovanna Boe, Mario Scartozzi, Eleonora Lai, Annagrazia Pireddu, Pina Ziranu, Laura Demurtas, Marco Puzzoni, Stefano Mariani, Andrea Pretta, Nicole Liscia, Clementina Savastano, Valentina Malaspina, Giuseppe Tonini, Teresa Grassani, Barbara Barco, Tagliaferri Pierosandro, Domenico Ciliberto, Antonella Ierardi, Natale Daniele Calandruccio, Vincenzo Minotti, Roberta Matocci, Valter Torri, Luca Porcu, Erica Rulli, Irene De Simone, Luciano Carlucci, Eliana Rulli, Davide Poli, Paola Tonto, Francesca Scellato, Carmine Pinto
Background: Information about the adherence to scientific societies guidelines in the ‘real-world’ therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f827f8705c922ff764aa383826811530
https://hdl.handle.net/11585/919206
https://hdl.handle.net/11585/919206
Autor:
Lorenzo Antonuzzo, Serena Pillozzi, Evaristo Maiello, Francesco Di Costanzo, Luca Boni, Ermanno Rondini, Tiziana Latiano, Cinzia Lamperini, Vanja Vaccaro, Guido Giordano, Caterina Vivaldi, Giampaolo Tortora, Elisa Giommoni, Laura Toppo
Publikováno v:
Current Oncology
Volume 28
Issue 3
Pages 164-1772
Current Oncology, Vol 28, Iss 164, Pp 1761-1772 (2021)
Volume 28
Issue 3
Pages 164-1772
Current Oncology, Vol 28, Iss 164, Pp 1761-1772 (2021)
Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most pat